Alzheimer’s disease blood-based biomarkers: A clinical and laboratory perspective

This webinar was recorded live on November 12, 2024.
It is available on demand through November 30, 2025.
Register above for access

Description

This webinar is for laboratorians, clinicians, and other stakeholders interested in learning about Alzheimer’s Disease, the new anti-amyloid FDA approved therapies, and the use of blood-based biomarkers in the patient journey, especially their role in diagnosing early-stage Alzheimer’s disease.

This webinar will offer a clinician’s perspective on the importance of these novel diagnostic tools in detecting amyloid pathology in individuals presenting with cognitive impairment and how they can be integrated into clinical practice, as well as a clinical laboratory perspective on Alzheimer’s biomarker implementation. This activity is meant to offer insights into the best practices to incorporate blood-based biomarker tests in the standard of care for patients suspected of Alzheimer’s disease.

Target audience

This activity is designed for physicians, lab supervisors, lab directors (and/or assistant directors), lab managers (supervisory and/or non-supervisory), fellows, residents, in-training individuals, nurses, payors, healthcare administrators, and other laboratory professionals overseeing/conducting within this topic.

Learning objectives

At the end of this session, participants will be able to:

• Recognize the role of blood-based biomarkers in detecting amyloid pathology in early stages of Alzheimer’s Disease for potential initiation of anti-amyloid targeting therapies.
• Determine how to validate Alzheimer’s blood-based biomarkers in the clinical laboratory.
• Identify best practices for the implementation and use of Alzheimer’s Disease blood-based biomarkers, in clinical practice and laboratory.

Faculty

Alicia Algeciras-Schimnich, PhD
Professor Laboratory Medicine and Pathology
Co-Director Clinical Immunoassay Laboratory
Mayo Clinic
Rochester, MN, USA

Vijay Ramanan, MD, PhD
Consultant and Assistant Professor, Department of Neurology
Mayo Clinic 
Rochester, MN, USA

Disclosures and statement of independence

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

• Alicia Algeciras-Schimnich, PhD
  • Honorarium/Expenses: Roche Diagnostics
  • Board/Committee Membership/Advisory Board: Roche Diagnostics, Fujirebio Diagnostics
• Vijay Ramanan, MD, PhD
  
  • Grant/Research Support: Eisai, Transposon Therapeutics, Inc.

Content validity

All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Accreditation statement

This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID #4347. This activity was planned in accordance with ACCENT® Standards and Policies.

Successful completion statement

Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].